LifeSpex developing tissue spectroscopy technology for cervical cancer detection.
This article was originally published in The Gray Sheet
Executive Summary
LIFESPEX PMA SUBMISSION FOR SPECTROSCOPY-BASED PAP SMEAR ALTERNATIVE is expected in 18 to 24 months, the Houston-based startup says. The firm estimates a premarket approval application could be ready for submission to FDA within two years for a device using tissue spectroscopy to screen and/or diagnose cancerous and precancerous lesions of the cervix. LifeSpex has no immediate plans to submit an investigational device exemption to the agency and still is in the process of deciding whether to pursue a screening or diagnostic indication.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.